CureVac N.V. Revenue 2011-2026 | CVAC

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue CureVac N.V.

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	48.9 M	17.4 M	12.9 M	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
48.9 M	12.9 M	26.4 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	912 K	$ 1.06	-0.93 %	$ 5.78 M	China
Ascendis Pharma A/S ASND	364 M	$ 201.94	-3.26 %	$ 5 B	Danmark
Autolus Therapeutics plc AUTL	242 K	$ 1.82	-4.85 %	$ 464 M	Britain
Adagene ADAG	10.2 M	$ 1.65	-	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	109 K	$ 3.45	3.6 %	$ 8.3 B	Australia
Arrowhead Pharmaceuticals ARWR	829 M	$ 64.9	-0.15 %	$ 8.68 B	USA
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Biogen BIIB	9.68 B	$ 187.4	0.75 %	$ 27.3 B	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
BioXcel Therapeutics BTAI	2.27 M	$ 1.98	-1.0 %	$ 5.02 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
CASI Pharmaceuticals CASI	30.2 M	$ 1.04	-2.34 %	$ 142 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Catalyst Biosciences CBIO	113 M	$ 10.74	-2.1 %	$ 707 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	7.02 M	$ 27.0	-1.28 %	$ 1.74 M	USA
Cellectis S.A. CLLS	41.5 M	$ 4.42	-1.34 %	$ 116 M	France
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	60.3 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	482 M	$ 99.81	0.97 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	732 M	$ 27.75	0.02 %	$ 1.34 B	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 4.14	-3.72 %	$ 9.01 B	Israel
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	463 M	$ 11.13	-2.02 %	$ 720 M	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Axon Enterprise AXON	2.08 B	$ 633.45	3.34 %	$ 48 B	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	66.4 M	$ 2.64	-0.75 %	$ 16.6 M	USA
BeiGene, Ltd. BGNE	3.81 B	-	0.49 %	$ 251 B	Cayman-islands
AstraZeneca PLC AZN	54.1 B	$ 94.65	0.68 %	$ 96.9 B	Britain
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA